976
SHORT COMMUNICATION
Periorbital Involvement in Early Stage Mycosis Fungoides
Iris WIESER 1,2 , Auris HUEAN 1 , Amelia E. BUSH 3 , Boutnaina S. DABAJA 4 and Madeleine DUVIC 1
Departments of 1 Dermatology and 4 Radiation Oncology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston,
TX 77030-4095, USA, 2 Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, and 3 University of Texas Medical School
at Houston, Houston, Texas, USA. E-mail: [email protected]
Accepted Apr 18, 2017; Epub ahead of print Apr 19, 2017
Mycosis fungoides (MF) is the most common form of
cutaneous T-cell lymphomas (CTCL) and accounts for
approximately 50% of all CTCL (1, 2). Classically, it
presents with erythematous patches on sun-protected
areas 2–10 years before confirmed on skin biopsy (3).
Approximately 10% of patients initially presenting with
patches will subsequently progress to advanced stages
of disease (4). Since its first description, MF continues
to evolve with discovering of new variants (2).
Periorbital involvement is a rare finding in MF and is
usually associated with advanced stages of disease. In
1892, Besnier & Hallopeau reported the first patient with
periorbital involvement, and extensive and ultimately,
fatal disease (5). While the majority of cases describe
patients with advanced stages, to date only few reports
of isolated periorbital involvement, in early stage MF
have been published (6–11).
Herein, we report the clinical, epidemiological and
histopathological presentation of 7 patients with biopsy
proven early stage MF and periorbital lesions.
PATIENTS AND METHODS
We conducted a retrospective study of patients seen with perior-
bital MF lesions, at the CTCL clinic at the MD Anderson Cancer
Center, Houston Texas. The study protocol was approved by the
institutional review board (#PA16-0091). Additional informed
consent was obtained from all individual participants for whom
identifying information is included in this article. Electronic medi-
cal records and paper-based flow charts were screened for patients
with periorbital involvement in MF. Clinical and histopathological
data were re-evaluated. Diagnosis and staging of MF were made
by a CTCL expert (M.D), according to the modified International
Society of Cutaneous Lymphomas/European Organization for
Research and Treatment of Cancer revisions of the TNMB Clas-
sification of MF and Sézary syndrome (1).
All analyses were conducted using SPSS version 22.0 (IBM
Corporation, Armonk, NY, USA). Continuous data are expressed
as mean ± standard deviation (SD) and median (range), as appro-
priate. Basic summary statistics were used to describe demographic
data, treatment modalities, and response.
RESULTS
A total of 7 patients were evaluated, and their clinical cha-
racteristics are summarized in Table SI 1 . The mean ± SD
age